AllSight
Companies · SION · Pharmaceutical Preparations

Sionna Therapeutics, Inc. (SION)

Sionna Therapeutics, Inc. (SION) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Sionna Therapeutics, Inc. (SION) stock — financials & valuation

Key numbers for Sionna Therapeutics, Inc. (SION): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 50/100 — a percentile rank of Sionna Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$269.5M
EV / EBITDA-1.9×
Return on equity-36.6%
ROIC-54.1%
Debt / equity0.0×
Dividend yield0.0%

Independent of the events above — derived from Sionna Therapeutics, Inc.’s own financial statements and shown as context, never as advice.

Sep 14, 2026Phase 2a pivot
Sionna pivots to Phase 2a after failed CF readout, cuts 46% of workforce
Aug 10, 2026
Phase 2a misses its activity endpoint; SION-719 add-on is shelved
Aug 6, 2026
Clinical milestones stay on track; spending and losses deepen ahead of key data
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact